Xencor Ends Ultomiris Royalty Dispute with $105M Settlement, Extending Cash Runway to 2028

summarizeSummary

Xencor will receive $105 million from Alexion to resolve a dispute over U.S. Ultomiris royalties, eliminating a key uncertainty and extending its cash runway through 2028.

check_boxKey Events · Legal and Risk Events · XNCR

• Settlement Agreement with Alexion

  To resolve a commercial dispute over U.S. royalties on Ultomiris, Xencor entered into a settlement agreement with Alexion. The deal delivers $105 million in two equal payments: $52.5 million in August 2026 and $52.5 million on the one-year anniversary of the agreement.

• Financial Impact

  The $105 million settlement provides immediate capital and removes uncertainty around a previously expected royalty stream. Alexion will have no further obligation to pay U.S. royalties, but ex-U.S. royalties remain unchanged under the existing license agreement.

• Cash Runway Extended

  Based on current operating plans, Xencor now expects to have sufficient cash to fund research and development programs and operations through 2028, an improvement from prior guidance.

• Dispute Background

  In March 2026, Alexion had informed Xencor that it believed no additional U.S. royalties were owed and would not make future payments. The settlement fully resolves this dispute.

auto_awesomeAnalysis · XNCR · Life Sciences

A commercial dispute over U.S. royalties on Ultomiris has been resolved, with Xencor set to receive $105 million from Alexion in two installments. The first $52.5 million arrives in August 2026, and the second follows a year later. In return, Alexion is released from any further U.S. royalty obligations, though ex-U.S. royalties continue unchanged. Eliminating this major uncertainty—which had threatened a key revenue stream—extends the company's cash runway through 2028, a critical lifeline for a clinical-stage biotech facing widening losses and insider selling.